Show simple item record

dc.contributor.author Ötvös, László
dc.contributor.author Vetter SW
dc.contributor.author Koladia M
dc.contributor.author Knappe D
dc.contributor.author Schmidt R
dc.contributor.author Ostorházi, Eszter
dc.contributor.author Kovalszky, Ilona
dc.contributor.author Bionda N
dc.contributor.author Cudic P
dc.contributor.author Surmacz E
dc.contributor.author Wade JD
dc.contributor.author Hoffmann R
dc.date.accessioned 2016-11-23T13:31:20Z
dc.date.available 2016-11-23T13:31:20Z
dc.date.issued 2014
dc.identifier 84898927167
dc.identifier.citation pagination=873-882; journalVolume=46; journalIssueNumber=4; journalTitle=AMINO ACIDS;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2963
dc.identifier.uri doi:10.1007/s00726-013-1650-6
dc.description.abstract The leptin receptor antagonist peptide Allo-aca exhibits picomolar activities in various cellular systems and sub-mg/kg subcutaneous efficacies in animal models making it a prime drug candidate and target validation tool. Here we identified the biochemical basis for its remarkable in vivo activity. Allo-aca decomposed within 30 min in pooled human serum and was undetectable beyond the same time period from mouse plasma during pharmacokinetic measurements. The C max of 8.9 mug/mL at 5 min corresponds to approximately 22 % injected peptide present in the circulation. The half-life was extended to over 2 h in bovine vitreous fluid and 10 h in human tears suggesting potential efficacy in ophthalmic diseases. The peptide retained picomolar anti-proliferation activity against a chronic myeloid leukemia cell line; addition of a C-terminal biotin label increased the IC50 value by approximately 200-fold. In surface plasmon resonance assays with the biotin-labeled peptide immobilized to a NeutrAvidin-coated chip, Allo-aca exhibited exceptionally tight binding to the binding domain of the human leptin receptor with k a = 5 x 105 M-1 s-1 and k diss = 1.5 x 10-4 s-1 values. Peptides excel in terms of high activity and selectivity to their targets, and may activate or inactivate receptor functions considerably longer than molecular turnovers that take place in experimental animals.
dc.relation.ispartof urn:issn:0939-4451
dc.title The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor
dc.type Journal Article
dc.date.updated 2015-12-07T14:19:17Z
dc.language.rfc3066 en
dc.identifier.mtmt 2502512
dc.identifier.wos 000333241800007
dc.identifier.pubmed 24366600
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.department SE/AOK/K/Bőr-, Nemikórtani és Bőronkológiai Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account